当前位置:首页 > 报告详情

JPM 2023 武田.pdf

上传人: 2*** 编号:142931 2023-09-30 21页 2.08MB

1、Committed to Long-term Growth&Shareholder Returns41stAnnual J.P.Morgan Healthcare ConferencePresident&CEOJanuary 9th,2023Christophe WeberFor the purposes of this notice,“presentation”means this document,any oral presentation,any question and answer session and any written or oral material discussed

2、or distributed by Takeda Pharmaceutical Company Limited(“Takeda”)regarding this presentation.This presentation(including any oral briefing and any question-and-answer in connection with it)is not intended to,and does not constitute,represent or form part of any offer,invitation or solicitation of an

3、y offer to purchase,otherwise acquire,subscribe for,exchange,sell or otherwise dispose of,any securities or the solicitation of any vote or approval in any jurisdiction.No shares or other securities are being offered to the public by means of this presentation.No offering of securities shall be made

4、 in the United States except pursuant to registration under the U.S.Securities Act of 1933,as amended,or an exemption therefrom.This presentation is being given(together with any further information which may be provided to the recipient)on the condition that it is for use by the recipient for infor

5、mation purposes only(and not for the evaluation of any investment,acquisition,disposal or any other transaction).Any failure to comply with these restrictions may constitute a violation of applicable securities laws.The companies in which Takeda directly and indirectly owns investments are separate

6、entities.In this presentation,“Takeda”is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.Likewise,the words“we”,“us”and“our”are also used to refer to subsidiaries in general or to those who work for them.These expressions are alsoused where no usefu

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文是Takeda Pharmaceutical Company Limited(Takeda)在2023年1月9日举行的第41届J.P. Morgan Healthcare Conference上的演讲稿。主要内容包括: 1. Takeda致力于成为最值得信赖、以科学驱动、数字化生物制药公司。 2. 2022财年上半年,Takeda的营收为3,930亿日元(约297亿美元),同比增长5.5%。 3. 预计2022财年,Takeda的营收将实现低个位数增长,核心营业收入将实现高个位数增长,核心每股收益将实现高个位数增长。 4. Takeda的增长和上市产品营收在2022财年上半年同比增长19%,其中免疫学、罕见病和血小板减少症产品表现强劲。 5. Takeda计划通过收购Nimbus Therapeutics的NDI-034858,进一步强化其免疫介导疾病治疗产品线。 6. Takeda将继续致力于长期增长和股东回报,包括扩大增长和上市产品、推进后期管线产品上市、减少损失独占权的影响等。
Takeda如何实现长期增长和股东回报? Takeda的哪些产品推动了收入增长? Takeda如何通过收购实现产品管线增强?
客服
商务合作
小程序
服务号
折叠